All articles tagged with #ucb
UCB's shares hit a record high after positive trial results for its drug Bimzelx, while MoonLake's stock plummeted following disappointing late-stage trial data for its drug sonelokimab, which showed inferior efficacy in treating hidradenitis suppurativa.
The FDA has approved UCB's Rystiggo, a treatment for generalized myasthenia gravis, making it the first drug to receive approval for both main subtypes of the rare autoimmune disease. UCB plans to make the under-the-skin treatment commercially available in the third quarter, following the recent approval of argenx's Vyvgart Hytrulo in subcutaneous form.